All News

Cell Therapy

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
23 March 2023
Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
Kite’s Yescarta CAR-T cell therapy
Autologous vs Allogeneic: What Therapeutic Developers and Manufacturers Really Need to Know
16 March 2023
Autologous vs Allogeneic: What Therapeutic Developers and Manufacturers Really Need to Know
Rupa Pike, Senior Director of
GOSH Enters into Agreement with Leucid Bio at a New Therapy Manufacturing Center
16 March 2023
GOSH Enters into Agreement with Leucid Bio at a New Therapy Manufacturing Center
Leucid Bio, announced an agreement
Pfizer Invests $43 Billion to Acquire Seagen
14 March 2023
Pfizer Invests $43 Billion to Acquire Seagen
Pfizer is to acquire global
POPULAR NEWS ITEMS
Image
23 March 2023

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image
14 March 2023

Pfizer Invests $43 Billion to Acquire Seagen

Image
2 March 2023

Early Adoption and Partnerships – The Secret to Commercialization Success?

Adaptimmune and TCR2 Collaborate to Develop Cell Therapies for Solid Tumors
8 March 2023
Adaptimmune and TCR2 Collaborate to Develop Cell Therapies for Solid Tumors
Adaptimmune Theraputics and TCR2 Theraputics
Coffee and a Cupcake: a Spotlight on Women in Advanced Therapies
8 March 2023
Coffee and a Cupcake: a Spotlight on Women in Advanced Therapies
Becky Johnson-Kent, Program Lead for
Manufacture of Healthy and Highly Functioning Gene-Edited Immune Cells
8 March 2023
Manufacture of Healthy and Highly Functioning Gene-Edited Immune Cells
Are you looking to engineer
Early Adoption and Partnerships – The Secret to Commercialization Success?
2 March 2023
Early Adoption and Partnerships – The Secret to Commercialization Success?
This Briefing from Advanced Therapies
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image

Pfizer Invests $43 Billion to Acquire Seagen

Image

Early Adoption and Partnerships – The Secret to Commercialization Success?